Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Pipeline Updates:
TREVOSE, Pa., Feb. 1, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today reported financial results for its fiscal 2023 second quarter ended December 31, 2022.
"For the quarter, net sales, gross margin and adjusted gross margin increased compared with the two preceding quarters," said Tim Crew, chief executive officer of Lannett. "This improved performance was in part driven by higher product sales across our offering, notably, generic Adderall due to an ongoing market shortage where our partner was able to maintain their supply; the sale of certain products under a private label agreement; and less competitive intensity than we anticipated. During the quarter, we received, as expected, approximately $19 million of income tax refunds.
"With regard to our pipeline, we are nearing the launch, subject to approval, of a few products that have the potential to be meaningful contributors to our financial results. For our biosimilar insulin glargine product, initial results from the pivotal trial are expected shortly; and with regard to our biosimilar insulin aspart product, positive results from the animal study indicated that our product was highly comparable to the reference biologic. Importantly, we previously entered into a supply agreement for a pen injector delivery device for use with our biosimilar insulin glargine and biosimilar insulin aspart products. Recently we acquired a sublicense to the various patents held by the reference product owner, related to the pen injector device, thereby removing potential related litigation risk associated with the insulin glargine product and improving our ability to freely market our biosimilar insulin products, once approved.
"Looking ahead, we have raised our full-year guidance for net sales and adjusted gross margin, which reflects, in part, our improved performance over the first half of our current fiscal year and our belief that our and our partners' reliable and high-quality supply of affordable medicines has contributed to some stabilization of our current business."
Restructuring, Cost Reduction Initiatives
In December 2022, the company authorized a restructuring and cost savings plan that, once fully implemented, is estimated to generate cost savings of approximately $11 million, annually. The plan includes operational improvements and cost efficiencies, as well as a restructuring of the company's research and development (R&D) function. These actions will result in a workforce reduction of approximately 60 staffed positions and 40 recently vacant positions, which will be implemented in phases over the remainder of the company's current fiscal year. The company also anticipates exiting two facilities located in Philadelphia, Pennsylvania this year. While the plan is expected to reduce certain R&D-related costs, the company plans to maintain its level of investment in product development.
Second-Quarter Financial Results: Fiscal 2023 vs Fiscal 2022
GAAP basis:
Non-GAAP basis:
Posted In: LCI